Phase 3 Cardiomyopathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Women between the ages of 18 and 50 years old
- People diagnosed with ischemic cardiomyopathy (heart muscle damage caused by reduced blood flow) or de novo dilated cardiomyopathy (a newly diagnosed condition where the heart muscle is weakened and enlarged)
Who may not be able to join:
- People with serious other health conditions that could make their illness worse
- People with heart disease caused by high blood pressure
- People with heart valve disease caused by rheumatic fever
- People with certain types of heart muscle disease, including restrictive, constrictive, or hypertrophic cardiomyopathy (conditions where the heart muscle is stiff, thickened, or otherwise abnormal in specific ways)
- People with heart defects that were present from birth
- People who have recently had a heart attack or acute coronary syndrome (a sudden, serious reduction in blood flow to the heart)
- People with significant kidney problems, indicated by a specific blood test result (serum creatinine of 1.4 mg/dl or higher)
- Women who have had peripartum cardiomyopathy (heart failure related to pregnancy) in the past, are currently pregnant, are planning to become pregnant during the study, or are currently breastfeeding
- People who have previously had a bad reaction to the medication bromocriptine
- People who do not wish to take part in the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Kedir N Tukeni, MD, Jimma University
Phone: +251913521475
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Left ventricular function improvement; Improvement of cardiac biomarkers (N-terminal Pro BNP); Clinical improvement assessment tests
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.